Search
"Through the first 2.5 years of the program, M2CC has delivered over 13,000 prescriptions with an estimated gross revenue of $3.5 million" Butts et al (2023).

Ambulatory oncology infusion delivery service study

Abstract:

Objective: Patients receiving infusions for the treatment of cancer are commonly prescribed supportive care medications which are filled through retail pharmacies. The initial phase of the COVID-19 pandemic created hurdles for patients to receive supportive care medications due to concerns related to exposure risk. Meds-to-Chemo Chairs (M2CC) was created allowing an onsite retail pharmacy to dispense and hand-deliver supportive care prescriptions to patients in the infusion suite. The purpose of this study was to assess the value of this program.

Data sources: The volume of prescriptions dispensed through the M2CC service, as well as the financial impact, was tracked through the prescription software system used by the onsite retail pharmacy dispensing and delivering the medications.

Data summary: Through the first 2.5 years of the program, M2CC has delivered over 13,000 prescriptions with an estimated gross revenue of $3.5 million.

Conclusions: The M2CC medication delivery program has proved to be highly successful and feasible.


Reference:

Butts AR, Ellis CS, Travers EA, Reynolds JW, Rogers LE, Otto DE, Schwieterman PA. Implementation of a medication delivery service for ambulatory oncology infusion patients. J Oncol Pharm Pract. 2023 Jul 10:10781552231185527. doi: 10.1177/10781552231185527. Epub ahead of print. PMID: 37431207.

Register for free citation alerts

Supporting your vascular access and infusion therapy learning journey